Cilag AG International
Business Park Sofia
Building 4, Floor 3<b>Mladost IV distr.
Mladost IV distr.
5 articles with Cilag AG International
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain
Cilag AG International Completes $245 Million Acquisition of Over-the-Counter Brands of JB Chemicals & Pharmaceuticals Limited
SuperGen, Inc. Announces Attainment Of Milestone From The MGI PHARMA, INC. / Cilag GmbH, A Johnson & Johnson, Licensing For Dacogen(TM) (Decitabine) For Injection